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Supplemental Figure 1 Metabolic pathway of vitamin D metabolites. C-3-epimerisation means configuration 
of the hydroxyl bond at the C-3 position between vitamin D metabolites, as indicated in the molecular figure for 
the structure change (direction change of -OH group) from non-epimeric 25(OH)D3 to 3-epi-25(OH)D3 in the 
dashed rectangle. Metabolites assayed in the current study are highlighted by bold rectangles. 
 
Supplemental Figure 2 EPIC-InterAct study design and participants included in the analysis 
 
Supplemental Figure 3 Distribution of baseline plasma 25(OH)D metabolites, dietary vitamin D and 
vitamin supplement intake by future diabetes case status and country: EPIC-InterAct Study. Values 
represent mean (bars: SD) for non-epimeric 25(OH)D3 and dietary vitamin D, median (error bar: interquartile 
range) for the other 25(OH)D metabolites, and percentage (%) for vitamin supplements. Numbers in the bar 
indicate sample size for the estimation. 
 
Supplemental Figure 4 Predicted levels of 25(OH)D metabolites by days of blood draw in the year: EPIC-
InterAct Study. The solid line represents the predicted mean of 25(OH)D metabolites given day of blood draw, 
which was modelled as a linear combination of sine and cosine functions, stratified by country. p-values for sine 
and cosine predictors were estimated by meta-analyzing the country-specific beta coefficients of sine and cosine 




Supplemental Figure 5 Prospective associations of plasma 25(OH)D metabolites with incident type 2 
diabetes by country: EPIC-InterAct Study. Hazard ratios (HRs) and 95% confidence intervals (CI) are per 1-
SD (calculated from the subcohort distributions) higher vitamin D metabolites, estimated using country-specific 
Prentice-weighted Cox regression models, adjusted for age (as underlying timescale), sex, center, seasonality 
(sine and cosine function of the day of blood draw), smoking status, physical activity, education, alcohol 
drinking, total energy intake, Mediterranean diet score, circulating lipid biomarkers (HDL-C, LDL-C), BMI and 
the other two 25(OH)D metabolites (i.e. Model 4). Country-specific estimates were combined using inverse 
variance-weighted random-effects meta-analysis. Mean (SD) values are from the subcohort only.  
 
Supplemental Figure 6 Association of the ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3 with 
incident type 2 diabetes: EPIC-InterAct Study. Panel (A): Hazard ratios (95%CI) of type 2 diabetes per 1-SD 
higher of the ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3, estimated using country-specific Prentice-
weighted Cox regression models, adjusted for age (as underlying timescale), sex, center, seasonality (sine and 
cosine function of the day of blood draw), smoking status, physical activity, education, alcohol drinking, total 
energy intake, Mediterranean diet score, circulating lipid biomarkers (HDL-C, LDL-C), BMI and 25(OH)D2 (i.e. 
Model 4). Country-specific estimates were combined using inverse variance-weighted random-effects meta-
analysis. Panel (B): Shape of the association of the ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3 with 
incident type 2 diabetes, calculated by the restricted cubic spline functions with 3 knots in country-specific 
Prentice weighted Cox regression models. We combined the country-specific estimates using a multivariate 
random-effects meta-analysis. We also plotted the hazard ratio (95%CI) across the quintiles 2-5 of the ratio 
(quintile 1 as reference, location of each plot corresponds to the median level within each quintile). Reference 
for the HR estimation was the 10th percentiles (-3.77 [equivalent to 0.023 in original scale]) of the ratio (log-
transformed).   
 
Supplemental Figure 7 Prospective association between plasma 25(OH)D3 metabolites and type 2 diabetes 
stratified by BMI categories: EPIC-InterAct Study. Interaction of 25(OH)D metabolites with age, sex, BMI, 
physical activity, hormone therapy use (among women only) and menopausal status (among women only) for 
type 2 diabetes was examined, and only BMI showed significant interaction (p<0.05) with both non-epimeric 
25(OH)D3 and 3-epi-25(OH)D3 (p-value < 0.001 for both). Hazard Ratios (HRs) and 95% confidence intervals 
(CI) are per 1-SD (calculated from the subcohort distributions) higher vitamin D metabolite, estimated using 
country-specific Prentice-weighted Cox regression models, stratified by three BMI subgroups. Country-specific 
estimates were combined using inverse variance-weighted random-effects meta-analysis. The adjusted 
covariates were age (as underlying timescale), sex, center, seasonality (sine and cosine function of the day of 
blood draw), smoking status, physical activity, education, alcohol drinking, total energy intake, Mediterranean 
diet score, circulating lipid biomarkers (HDL-C, LDL-C), BMI and the other 25(OH)D metabolites.  
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Supplemental Table 1 Population characteristics at baseline by future case and non-case status: EPIC-
InterAct Study*  
Non-cases (n=12980) Cases (n=9671) 
 Mean/% n/SD Mean/% n/SD 
Total 25(OH)D†‡ 41.3 17.3 37.2 16.2 
Non-epimeric 25(OH)D3, nmol/L†‡ 40.9 17.3 36.9 16.3 
3-epi-25(OH)D3, nmol/L†‡ 2.13 1.32 2.17 1.44 
Ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3†‡ 0.04 0.02 0.05 0.02 
25(OH)D2, nmol/L†‡ 8.18 6.57 7.97 5.65 
Age, y‡ 51.5 9.10 54.9 7.60 
BMI, kg/m2‡ 26.0 4.10 29.9 4.70 
Sex, %       
Men 36.9 4784 49.9 4829 
Women 63.1 8196 50.1 4842 
Total energy intake, kcal/d‡ 2126 636 2165 676 
Alcohol consumption, %       
None 16.1 2085 17.9 1733 
>0-<6g/d 34.3 4447 32.2 3117 
6-<12g/d 14.5 1888 13.1 1266 
12-<24g/d 15.5 2012 14.3 1381 
≥24g/d 19.3 2502 21.8 2110 
Mediterranean diet score, %       
Low (score 0-6)  22.5 2919 27.4 2652 
Moderate (score 7-10) 43.5 5643 40.9 3953 
High (score 11-18)  31.9 4135 28.3 2740 
Physical activity, %   
   
Inactive 23.5 3044 29.9 2894 
Moderately inactive 32.4 4206 31.5 3044 
Moderately active 22.3 2901 19.9 1928 
Active 20.3 2632 17.1 1653 
Smoking status, %   
   
Never 47.5 6166 41.4 4008 
Former 26.1 3392 29.4 2842 
Current 25.1 3255 27.7 2683 




None 8.20 1069 11.3 1095 
Primary 31.3 4060 39.7 3838 
Technical or professional 22.0 2862 23.0 2221 
Secondary 15.9 2062 11.0 1062 
Higher education 20.4 2651 12.4 1195 




Winter (Dec-Feb) 24.3 3154 23.9 2310 
Spring (Mar-May) 27.8 3606 27.9 2701 
Summer (June-Aug) 19.9 2587 20.6 1992 
Autumn (Sept-Nov) 27.8 3604 27.4 2646 
*SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids. 
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† Sample size was 12980 among non-cases and 9671 among cases for the measured non-epimeric 25(OH)D3; 
5292 among non-cases and 3694 among cases for measured 3-epi-25(OH)D3; 615 among non-cases and 397 
among non-cases for measured 25(OH)D2. Total 25(OH)D: sum of non-epimeric 25(OH)D3 + 25(OH)D2. 




Supplemental Table 2 Population characteristics by quintiles of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3 ratio, and 25(OH)D2 in the subcohort of EPIC-InterAct 
Study* 
  
Quintiles of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3 ratio Quintiles of 25(OH)D2 
 3-epi-
25(OH)D3 
below LLQ † 
(n=8049) 
Q1 (n=1102) Q2 (n=1103) Q3 (n=1102) Q4 (n=1103) Q5 (n=1103) Below 
LLQ‡(n=12928) 
Q1 (n=126) Q2 (n=127) Q3 (n=127) Q4 (n=127) Q5 (n=127) 
Total 25(OH)D§ 34.9 (14.5) 58.8 (13.1) 51.2 (14.2) 48.4 (15.5) 46.7 (17) 45.2 (20.2) 40.9 (17.3) 44.5 (16.3) 47.2 (17.9) 41 (16) 43.1 (14.9) 47.8 (15.9) 
Non-epimeric 25(OH)D3, 
nmol/L 
34.4 (14.5) 58.6 (13.1) 51.0 (14.1) 48.1 (15.5) 46.4 (17) 44.8 (20.3) 40.9 (17.3) 41.2 (16.3) 42.9 (18) 34.8 (16.2) 34.2 (15) 30.3 (17.5) 
3-epi-25(OH)D3, nmol/L  1.3 (0.3) 1.6 (0.5) 1.9 (0.6) 2.4 (0.9) 3.5 (2.1) 2.1 (1.3) 2.1 (1.3) 2.3 (1.2) 2.0 (1.0) 2.0 (1.5) 2.5 (3.4) 
3-epi-25(OH)D3 to non-
epimeric 25(OH)D3 ratio 
 0.02 (0.003) 0.03 (0.002) 0.04 (0.003) 0.05 (0.004) 0.08 (0.02) 0.04 (0.02) 0.04 (0.02) 0.04 (0.02) 0.05 (0.02) 0.05 (0.03) 0.05 (0.02) 
25(OH)D2, nmol/L 8.7 (7.0) 6.2 (3.4) 6.2 (3.5) 7.4 (5.4) 6.6 (3.5) 8.8 (8.1) 
 
3.4 (0.2) 4.3 (0.4) 6.2 (0.7) 8.9 (1) 18 (8.5) 
Age, y 51.7 (9.0) 50.7 (9.7) 51.3 (9.3) 52 (9.2) 51.7 (8.7) 51.2 (8.9) 51.5 (9.1) 52.3 (8.9) 54.4 (9.1) 54.1 (7.5) 54.7 (8.2) 54.4 (7.7) 
BMI, kg/m2 26.3 (4.4) 25.2 (3.9) 25.5 (3.8) 25.9 (3.9) 26.2 (4.2) 26.5 (4.1) 26.2 (4.2) 24.8 (3.7) 25.3 (4.1) 25.4 (4) 25.8 (4.6) 25.1 (3.4) 
Energy intake, kcal/d 2111 (633) 2093 (630) 2112 (643) 2126 (622) 2181 (658) 2235 (657) 2128 (641) 2100 (563) 2161 (588) 2098 (526) 2172 (566) 1966 (547) 
Sex, %             
Men 34.3 32.3 37.9 39.7 46.1 52.3 37.4 28.6 40.9 38.6 44.1 26.8 
Women 65.7 67.7 62.1 60.3 53.9 47.7 62.6 71.4 59.1 61.4 55.9 73.2 
Alcohol consumption, %             
0 g/d 18.1 14.1 14 14.6 14.1 11.3 16.5 18.3 6.3 9.4 9.4 15.7 
>0-<6 g/d 35.2 40.0 36.4 31.3 30.0 24.3 34.2 31.7 31.5 29.1 28.3 33.9 
6-<12 g/d 14 17.7 15.5 15.1 14.8 12.3 14.2 16.7 21.3 17.3 18.9 23.6 
12-<24 g/d 15.1 14.2 16.0 17.9 14.9 17.2 15.4 17.5 20.5 22.0 15.0 12.6 
≥24 g/d 17.3 13.7 17.9 20.7 26.0 34.1 19.4 15.9 20.5 22.0 28.3 14.2 
Mediterranean diet score, %             
Low (score 0-6)  21.9 27.1 25.2 22.1 21.1 21.0 22.4 22.2 24.4 27.6 26.8 16.5 
Moderate (score 7-10) 43.2 42.8 45.5 43.2 43.2 43.4 43.1 50.8 45.7 46.5 48.0 55.1 
High (score 11-18)  32.7 28 27 32.5 33.4 32.8 32.2 25.4 29.1 25.2 22.0 25.2 
Physical activity, %             
Inactive 26.1 18.9 20.5 21.2 20.6 20.6 23.9 21.4 20.5 16.5 16.5 24.4 
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Moderately inactive 33.0 29.4 31.7 32.4 32.0 32.4 32.4 29.4 33.9 34.6 31.5 33.9 
Moderately active 21.6 25.3 23.8 21.5 22.8 22.0 22.1 26.2 23.6 24.4 26.8 18.1 
Active 17.6 24.5 22.7 23.6 23.7 23.9 20.0 19.8 20.5 23.6 23.6 22.8 
Smoking status, %             
Never 48.3 49.9 47.9 47.6 43.2 40.2 47.2 50.8 46.5 46.5 48.8 50.4 
Former 24.5 27.9 26.7 26.8 30.2 32.0 26.2 28.6 34.6 26.0 25.2 20.5 
Current 26.2 20.2 23.8 24.5 24.9 26.5 25.4 19.8 17.3 26.8 25.2 27.6 
Educational level, %             
None 9.2 5.4 6.4 7.6 9.4 9.8 8.9 1.6 3.1 0 2.4 4.7 
Primary 32.3 27.5 29.3 32.6 33.2 32.3 32 30.2 22.0 28.3 26.0 24.4 
Technical or professional 21.4 24.8 24.2 23.2 21.2 22.1 21.8 23.8 26.0 29.9 32.3 26.0 
Secondary 15.4 18.4 17.0 15.2 14.6 14.1 15.5 15.9 20.5 17.3 11.8 16.5 
Higher education 19.8 21.3 20.8 19.0 20.0 20.1 19.7 25.4 26.8 22.0 25.2 28.3 
Season of blood draw, %             
Winter (Dec-Feb) 29.1 16.4 18.3 16.9 19.1 16.5 24.4 23.0 16.5 25.2 29.1 28.3 
Spring (Mar-May) 31.3 18.8 22.8 25.1 23.6 24.1 27.7 27.8 25.2 35.4 34.6 30.7 
Summer (June-Aug) 14.7 24.5 24.2 26.5 28.1 33.7 19.9 27.0 21.3 18.9 13.4 17.3 
Autumn (Sept-Nov) 24.7 40.0 34.7 31.0 28.8 25.7 27.8 21.4 36.2 20.5 22.8 23.6 
*All values are expressed as mean (SD) or as percentage; 
†This category represents that the ratio is missing because 3-epi-25(OH)D3 is the below LLQ (1 nmol/L); 
‡LLQ, lower limit of quantification. The LLQ for 25(OH)D2 is 3 nmol/L.  
§total 25(OH)D: sum of non-epimeric 25(OH)D3 + 25(OH)D2.
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Supplemental Table 3 Pairwise correlation of plasma 25(OH)D metabolites in the subchort of EPIC-InterAct Study* 
 
Non-epimeric 23(OH)D3 and 3-epi-
25(OH)D3 
 
Non-epimeric 23(OH)D3 and 25(OH)D2 
 
3-epi-25(OH)D3 and 25(OH)D2 
 
n r p n r p n r p 
Total subcohort 5513 0.44 <0.001 634 -0.30 <0.001 222 -0.11 0.109 
France 204 0.45 <0.001 49 -0.39 0.006 17 0.46 0.066 
Italy 796 0.49 <0.001 46 -0.17 0.266 13 0.21 0.494 
Spain 1292 0.47 <0.001 68 -0.18 0.135 25 -0.16 0.444 
UK 508 0.42 <0.001 73 -0.10 0.421 25 0.04 0.864 
Netherland 583 0.42 <0.001 45 -0.28 0.066 17 -0.07 0.779 
Germany 838 0.42 <0.001 52 -0.39 0.004 16 -0.06 0.816 
Sweden 477 0.43 <0.001 40 -0.37 0.019 19 -0.37 0.117 
Denmark 815 0.50 <0.001 261 -0.34 <0.001 90 -0.35 <0.001 
* EPIC-InterAct subcohort participants were used to calculate the statistics (Spearman’s correlation coefficients) across the eight countries and in the total subcohort.
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Supplemental Table 4 Association of demographic, lifestyle, dietary factors or circulating biomarkers with plasma 25(OH)D metabolites in the EPIC-InterAct 
subcohort 
 
25(OH)D metabolites Factors evaluated as potential correlates with 25(OH)D metabolites Complete case analysis  Analysis using multiple imputation 
n Beta* 95%CI I2, %  Beta 95%CI I2, % 
Non-epimeric 25(OH)D3, nmol/L 
(n=13562) † 
Demographic and lifestyle factors         
 
Sex (women vs men) 11369 -0.063 -0.158, 0.031 74.1  -0.060 -0.147, 0.026 80.9 
 Age (per 5y) 11369 -0.007 -0.026, 0.012 57.7  -0.005 -0.024, 0.013 63.0 
 BMI (per 5kg/m2) 11369 -0.113 -0.135, -0.091 0  -0.118 -0.138, -0.098 0 
 Alcohol (per 10g/d) 11369 0.026 -0.004, 0.055 80.9  0.017 -0.006, 0.041 76.4 
 Former vs never smoker 11369 0.084 0.037, 0.131 22.9  0.078 0.032, 0.125 31.9 
 Current vs never smoker 11369 -0.080 -0.135, -0.025 32.3  -0.088 -0.133, -0.042 19.8 
 Moderate inactive vs inactive 11369 0.104 0.061, 0.147 0  0.122 0.076, 0.169 15.6 
 Moderate active vs inactive 11369 0.191 0.107, 0.275 59.0  0.203 0.133, 0.273 50.3 
 Active vs inactive 11369 0.301 0.246, 0.357 0  0.298 0.247, 0.350 0 
 Middle vs low education level 11369 0.006 -0.036, 0.047 0  -0.010 -0.055, 0.035 21.6 
 High vs low education level  11369 -0.003 -0.094, 0.088 64.3  0.002 -0.078, 0.081 60.9 
 Latitudes (per 1000km) 11369 0.185 0.153, 0.217 NA‡  0.176 0.145, 0.206 NA 
 Dietary vitamin D and supplements         
 Vitamin supplements (yes vs no) 11369 0.116 0.011, 0.221 86.9  0.115 0.016, 0.213 86.2 
 Dietary vitamin D (per 10g/d) 11490 
 
0.297 0.140, 0.454 62.7  0.325 0.170, 0.480 67.7 
 Dietary food sources         
 Fish (per 100g/d) 11369 0.058 0.002, 0.113 0  0.102 0.021, 0.182 31.4 
 Egg (per 100g/d) 11369 0.014 -0.089, 0.116 0  0.043 -0.055, 0.140 0 
 Red meat (per 100g/d) 11369 0.022 -0.036, 0.079 0  0.021 -0.044, 0.085 22.4 
 Dairy products (per 100g/d) 11369 0.007 -0.001, 0.015 0.60  0.007 -0.001, 0.015 0 
 Total cereal (per 100g/d) 11369 -0.027 -0.048, -0.006 0  -0.03 -0.052, -0.008 16.8 
 Poultry (per 100g/d) 11369 -0.077 -0.222, 0.067 51.2  -0.037 -0.160, 0.086 43.5 
 Processed meat (per 100g/d) 11369 0.031 -0.075, 0.137 49.1  0.036 -0.035, 0.107 16.6 
 Offal (per 10g/d) 11369 0.004 -0.027, 0.035 0  0.007 -0.023, 0.036 0 
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25(OH)D metabolites Factors evaluated as potential correlates with 25(OH)D metabolites Complete case analysis  Analysis using multiple imputation 
n Beta* 95%CI I2, %  Beta 95%CI I2, % 
 Margarine (per 10g/d) 11369 0.032 -0.001, 0.065 63  0.036 -0.001, 0.073 73.8 
 Butter (per 10g/d) 11369 -0.042 -0.067, -0.017 0  -0.026 -0.049, -0.004 0 
 Mushroom (per 10g/d) 11369 -0.004 -0.033, 0.025 0  -0.006 -0.034, 0.021 0 
 Mediterranean diet score (per 1-category higher) 11490 
 
0.024 -0.003, 0.051 0  0.029 0.003, 0.054 0 
 Circulating biomarkers         
 SFA (per 1-SD) 11369 0.032 -0.007, 0.071 67.2  0.038 0.001, 0.074 69.1 
 PUFA (per 1-SD) 11369 0.079 0.038, 0.120 70.5  0.08 0.042, 0.119 72.7 
 HDL-cholesterol (per 1-SD) 11369 0.070 0.051, 0.089 0  0.072 0.054, 0.089 0 
 LDL-cholesterol (per 1-SD) 11369 0.019 -0.002, 0.040 29.3  0.019 -0.002, 0.040 38.3 
 Uric acid (per 1-SD) 11193 -0.002 -0.038, 0.033 52.9  -0.002 -0.033, 0.029 49.4 
 Creatinine (per 1-SD) 11193 0.152 0.122, 0.183 46.9  0.149 0.122, 0.176 41 
 AST (per 1-SD) 11193 -0.015 -0.043, 0.013 14.1  -0.011 -0.037, 0.016 17 
 ALT (per 1-SD) 11193 0.005 -0.022, 0.033 0  0.005 -0.020, 0.03 0 
 GGT (per 1-SD) 11193 -0.028 -0.051, -0.005 10.1  -0.03 -0.055, -0.005 27.7 
          
3-epi-25(OH)D3 (log-transformed) 
(n=13562) † 
Demographic and lifestyle factors         
 Sex (women vs men) 11369 -0.297 -0.494, -0.1 68.8   -0.268 -0.445, -0.09 78.2 
 Age (per 5y) 11369 -0.007 -0.044, 0.031 46.9  -0.011 -0.05, 0.029 60.9 
 BMI (per 5kg/m2) 11369 -0.131 -0.184, -0.079 0   -0.141 -0.188, -0.093 0 
 Alcohol (per 10g/d) 11369 0.116 0.078, 0.154 45.4   0.102 0.069, 0.135 43.9 
 Former vs never smoker 11369 0.108 0.014, 0.202 6.3   0.123 0.04, 0.207 0 
 Current vs never smoker 11369 -0.169 -0.286, -0.053 24.2   -0.154 -0.252, -0.057 12 
 Moderate inactive vs inactive 11369 0.166 0.047, 0.285 18.2   0.189 0.072, 0.305 25.8 
 Moderate active vs inactive 11369 0.245 0.102, 0.388 29.9   0.275 0.152, 0.399 21.4 
 Active vs inactive 11369 0.49 0.337, 0.644 28.1   0.486 0.369, 0.602 0 
 Middle vs low education level 11369 -0.006 -0.115, 0.103 19.5  -0.048 -0.157, 0.062 33 
 High vs low education level  11369 -0.011 -0.132, 0.109 5.3  -0.079 -0.186, 0.027 0 
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25(OH)D metabolites Factors evaluated as potential correlates with 25(OH)D metabolites Complete case analysis  Analysis using multiple imputation 
n Beta* 95%CI I2, %  Beta 95%CI I2, % 
 Latitudes (per 1000km) 11369 0.080 0.009, 0.152 NA  0.076 0.008, 0.144 NA 
 Dietary vitamin D and supplements         
 Vitamin supplements (yes vs no) 11369 0.098 -0.032, 0.228 56.1  0.117 -0.009, 0.244 59.1 
 Dietary vitamin D (per 10g/d) 11490 0.268 -0.101, 0.638 65.8  0.196 -0.16, 0.552 69.1 
 Dietary food sources         
 Fish (per 100g/d) 11369 0.046 -0.2, 0.293 52.6  0.049 -0.201, 0.299 61.2 
 Egg (per 100g/d) 11369 -0.054 -0.415, 0.308 40.3  0.043 -0.285, 0.371 40.7 
 Red meat (per 100g/d) 11369 0.062 -0.078, 0.202 6.5  0.047 -0.081, 0.175 5.4 
 Dairy products (per 100g/d) 11369 0.018 -0.006, 0.042 34  0.018 -0.002, 0.038 20.7 
 Total cereal (per 100g/d) 11369 -0.003 -0.051, 0.045 0  -0.007 -0.051, 0.038 0 
 Poultry (per 100g/d) 11369 0.034 -0.332, 0.399 61.6  0.034 -0.273, 0.342 54.4 
 Processed meat (per 100g/d) 11369 0.146 -0.005, 0.298 0  0.137 0, 0.274 0 
 Offal (per 10g/d) 11369 0.032 -0.046, 0.109 5.8  0.027 -0.043, 0.097 1.6 
 Margarine (per 10g/d) 11369 0.032 -0.028, 0.091 47.7  0.021 -0.045, 0.086 61.3 
 Butter (per 10g/d) 11369 -0.07 -0.136, -0.004 22.6   -0.063 -0.118, -0.007 12.8 
 Mushroom (per 10g/d) 11369 0.035 -0.032, 0.102 0  0.024 -0.039, 0.087 0 
 Mediterranean diet score (per 1-category higher) 11490 0.008 -0.055, 0.071 0  0.014 -0.044, 0.072 0 
 Circulating biomarkers         
 SFA (per 1-SD) 11369 0.091 0.016, 0.165 56.5   0.107 0.037, 0.177 59.9 
 PUFA (per 1-SD) 11369 0.022 -0.03, 0.073 16  0.012 -0.053, 0.077 53.4 
 HDL-cholesterol (per 1-SD) 11369 0.08 0.037, 0.124 0   0.082 0.042, 0.122 0 
 LDL-cholesterol (per 1-SD) 11369 -0.024 -0.079, 0.032 48.2  -0.023 -0.079, 0.033 57.4 
 Uric acid (per 1-SD) 11193 0.091 0.039, 0.142 0   0.077 0.03, 0.125 0 
 Creatinine (per 1-SD) 11193 0.11 0.063, 0.157 0   0.12 0.076, 0.165 0 
 AST (per 1-SD) 11193 0.05 -0.023, 0.123 33.2  0.054 0.001, 0.108 0.4 
 ALT (per 1-SD) 11193 -0.024 -0.126, 0.078 58.1  -0.033 -0.102, 0.035 25.9 
 GGT (per 1-SD) 11193 0.054 -0.006, 0.115 25.9  0.047 -0.003, 0.096 14.2 
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25(OH)D metabolites Factors evaluated as potential correlates with 25(OH)D metabolites Complete case analysis  Analysis using multiple imputation 
n Beta* 95%CI I2, %  Beta 95%CI I2, % 
          
Ratio of 3-epi-25(OH)D3 to non-
epimeric 25(OH)D3 (log-
transformed) (n=5513) † 
Demographic and lifestyle factors         
 Sex (women vs men) 4612 -0.155 -0.246, -0.065 18.3  -0.117 -0.191, -0.043 19.9 
 Age (per 5y) 4612 0.006 -0.025, 0.036 48.4  0 -0.023, 0.022 25.5 
 BMI (per 5kg/m2) 4612 0.037 -0.005, 0.079 0  0.046 0.008, 0.083 0 
 Alcohol (per 10g/d) 4612 0.069 0.033, 0.106 63.7  0.060 0.034, 0.085 46.9 
 Former vs never smoker 4612 0.046 -0.026, 0.117 0  0.050 -0.014, 0.114 0 
 Current vs never smoker 4612 0 -0.076, 0.076 0  0.014 -0.056, 0.083 0 
 Moderate inactive vs inactive 4612 -0.01 -0.118, 0.099 33  -0.012 -0.104, 0.081 24.8 
 Moderate active vs inactive 4612 -0.059 -0.169, 0.051 23.8  -0.048 -0.132, 0.036 0 
 Active vs inactive 4612 -0.007 -0.106, 0.091 0  0.003 -0.098, 0.105 17 
 Middle vs low education level 4612 0.044 -0.031, 0.119 0  0.029 -0.039, 0.097 0 
 High vs low education level  4612 -0.026 -0.117, 0.064 0  -0.042 -0.125, 0.040 0 
 Latitudes (per 1000km) 4612 -0.139 -0.193, -0.086 NA  -0.139 -0.189, -0.089 NA 
 Dietary vitamin D and supplements         
 Vitamin supplements (yes vs no) 4612 -0.046 -0.110, 0.018 0  -0.034 -0.094, 0.026 0 
 Dietary vitamin D (per 10g/d) 4662 -0.043 -0.251, 0.165 39.9  -0.120 -0.347, 0.107 56.2 
 Dietary food sources         
 Fish (per 100g/d) 4612 0.063 -0.090, 0.216 27.4  0.014 -0.152, 0.181 46.2 
 Egg (per 100g/d) 4612 0.003 -0.181, 0.187 0  -0.061 -0.231, 0.109 0 
 Red meat (per 100g/d) 4612 -0.035 -0.138, 0.067 0  -0.034 -0.130, 0.061 0 
 Dairy products (per 100g/d) 4612 0.010 -0.008, 0.027 21.2  0.010 -0.004, 0.023 0 
 Total cereal (per 100g/d) 4612 0.032 -0.006, 0.070 0  0.035 0, 0.070 0 
 Poultry (per 100g/d) 4612 0.105 -0.042, 0.252 0  0.075 -0.117, 0.267 30.5 
 Processed meat (per 100g/d) 4612 0.042 -0.074, 0.158 0  0.043 -0.061, 0.147 0 
 Offal (per 10g/d) 4612 0.037 -0.019, 0.093 0  0.041 -0.012, 0.095 0 
 Margarine (per 10g/d) 4612 -0.01 -0.060, 0.040 54.9  -0.009 -0.052, 0.034 48.2 
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25(OH)D metabolites Factors evaluated as potential correlates with 25(OH)D metabolites Complete case analysis  Analysis using multiple imputation 
n Beta* 95%CI I2, %  Beta 95%CI I2, % 
 Butter (per 10g/d) 4612 -0.012 -0.074, 0.050 40.2  -0.006 -0.056, 0.043 27.4 
 Mushroom (per 10g/d) 4612 0.043 -0.008, 0.094 0  0.044 -0.004, 0.092 0 
 Mediterranean diet score (per 1-category higher) 4662 -0.028 -0.077, 0.021 0  -0.026 -0.07, 0.0190 0 
 Circulating biomarkers         
 SFA (per 1-SD) 4612 0.019 -0.018, 0.056 0  0.013 -0.030, 0.056 34.3 
 PUFA (per 1-SD) 4612 -0.078 -0.140, -0.017 60.4  -0.098 -0.167, -0.028 75.9 
 HDL-cholesterol (per 1-SD) 4612 -0.023 -0.058, 0.012 0  -0.033 -0.065, -0.002 0 
 LDL-cholesterol (per 1-SD) 4612 -0.034 -0.064, -0.003 0  -0.031 -0.059, -0.003 0 
 Uric acid (per 1-SD) 4544 0.033 -0.045, 0.110 69.1  0.03 -0.026, 0.086 52.7 
 Creatinine (per 1-SD) 4544 -0.075 -0.115, -0.034 15.8  -0.083 -0.116, -0.050 0 
 AST (per 1-SD) 4544 0.016 -0.032, 0.064 11.6  0.018 -0.024, 0.059 4.8 
 ALT (per 1-SD) 4544 -0.012 -0.101, 0.077 65.6  -0.018 -0.102, 0.066 68.4 
 GGT (per 1-SD) 4544 0.071 0.001, 0.141 63.9  0.081 0.016, 0.146 66.3 
          
25(OH)D2 (log-transformed) 
(n=13562) † 
Demographic and lifestyle factors         
 Sex (women vs men) 11369 -0.035 -0.228, 0.157 NA  -0.021 -0.201, 0.158 NA 
 Age (per 5y) 11369 0.052 0.001, 0.103 NA  0.042 -0.005, 0.089 NA 
 BMI (per 5kg/m2) 11369 -0.052 -0.153, 0.049 NA  -0.091 -0.186, 0.003 NA 
 Alcohol (per 10g/d) 11369 -0.041 -0.092, 0.01 NA  -0.023 -0.069, 0.023 NA 
 Former vs never smoker 11369 -0.113 -0.286, 0.06 NA  -0.096 -0.257, 0.065 NA 
 Current vs never smoker 11369 -0.119 -0.305, 0.067 NA  -0.153 -0.328, 0.021 NA 
 Moderate inactive vs inactive 11369 -0.068 -0.267, 0.132 NA  -0.06 -0.248, 0.128 NA 
 Moderate active vs inactive 11369 -0.082 -0.301, 0.137 NA  -0.062 -0.269, 0.144 NA 
 Active vs inactive 11369 -0.133 -0.364, 0.097 NA  -0.124 -0.341, 0.094 NA 
 Middle vs low education level 11369 0.165 -0.016, 0.345 NA  0.156 -0.013, 0.325 NA 
 High vs low education level  11369 0.283 0.071, 0.495 NA  0.263 0.065, 0.461 NA 
 Latitudes (per 1000km) 11369 0.234 0.098, 0.369 NA  0.19 0.061, 0.32 NA 
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25(OH)D metabolites Factors evaluated as potential correlates with 25(OH)D metabolites Complete case analysis  Analysis using multiple imputation 
n Beta* 95%CI I2, %  Beta 95%CI I2, % 
 Dietary vitamin D and supplements         
 Vitamin supplements (yes vs no) 11369 1.095 0.918, 1.273 NA  1.038 0.87, 1.206 NA 
 Dietary vitamin D (per 10g/d) 11490 0.192 -0.151, 0.535 NA  0.061 -0.273, 0.395 NA 
 Dietary food sources         
 Fish (per 100g/d) 11369 0.061 -0.21, 0.333 NA  -0.025 -0.288, 0.238 NA 
 Egg (per 100g/d) 11369 -0.164 -0.613, 0.284 NA  -0.139 -0.568, 0.289 NA 
 Red meat (per 100g/d) 11369 0.07 -0.177, 0.317 NA  0.037 -0.196, 0.27 NA 
 Dairy products (per 100g/d) 11369 -0.02 -0.052, 0.012 NA  -0.004 -0.035, 0.026 NA 
 Total cereal (per 100g/d) 11369 -0.012 -0.106, 0.082 NA  -0.012 -0.1, 0.077 NA 
 Poultry (per 100g/d) 11369 -0.035 -0.405, 0.335 NA  -0.107 -0.466, 0.251 NA 
 Processed meat (per 100g/d) 11369 -0.034 -0.348, 0.281 NA  0.112 -0.17, 0.393 NA 
 Offal (per 10g/d) 11369 0.003 -0.146, 0.153 NA  0 -0.145, 0.145 NA 
 Margarine (per 10g/d) 11369 -0.025 -0.088, 0.037 NA  -0.031 -0.091, 0.029 NA 
 Butter (per 10g/d) 11369 -0.088 -0.191, 0.014 NA  -0.071 -0.166, 0.024 NA 
 Mushroom (per 10g/d) 11369 0.016 -0.087, 0.12 NA  0.037 -0.061, 0.135 NA 
 Mediterranean diet score (per 1-category higher) 11490 0.083 -0.033, 0.199 NA  0.085 -0.026, 0.196 NA 
 Circulating biomarkers         
 SFA (per 1-SD) 11369 -0.109 -0.199, -0.019 NA  -0.129 -0.213, -0.046 NA 
 PUFA (per 1-SD) 11369 -0.02 -0.109, 0.069 NA  -0.017 -0.099, 0.065 NA 
 HDL-cholesterol (per 1-SD) 11369 0.037 -0.042, 0.116 NA  0.024 -0.05, 0.098 NA 
 LDL-cholesterol (per 1-SD) 11369 -0.044 -0.119, 0.031 NA  -0.004 -0.073, 0.065 NA 
 Uric acid (per 1-SD) 11193 -0.013 -0.113, 0.086 NA  -0.025 -0.119, 0.069 NA 
 Creatinine (per 1-SD) 11193 -0.041 -0.13, 0.049 NA  -0.019 -0.104, 0.067 NA 
 AST (per 1-SD) 11193 0.035 -0.073, 0.144 NA  0.042 -0.06, 0.144 NA 
 ALT (per 1-SD) 11193 0.082 -0.035, 0.199 NA  0.074 -0.036, 0.184 NA 
 GGT (per 1-SD) 11193 -0.121 -0.214, -0.028 NA  -0.086 -0.167, -0.004 NA 
*Beta and 95%CI represent standardized difference in individual 25(OH)D metabolite (in SD unit) per 1-standardised unit/category change in demographic, lifestyle, dietary factors or 
circulating biomarkers. For non-epimeric 25(OH)D3 and ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3, linear regression was used to obtain the country-specific effect estimates, which 
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were combined across countries using random effects meta-analysis. For epimeric 25(OH)D3 and 25(OH)D2, the Tobit regression was used to obtain the effect estimate. For the multiple 
imputation analysis: linear/tobit regression with multiple imputations (10 imputed datasets) was used to obtained country-specific effect estimates [except for latitudes due to limited study center 
in some countries, or 25(OH)D2 due to limited sample size], which were combined across countries using random effects meta-analysis. Low education level: none or primary school completed; 
middle education level: technical/professional or secondary school; high education level: Longer education (including university degree). Dietary factors were standardized into per 10g/d for 
alcohol, offal, margarine, butter, mushroom and dietary vitamin D, and per 100g/d for fish, egg, red meat, dairy products, cereal, poultry and processed meat intake. Mediterranean diet score 
was divided into three categories: low (0-6), middle (7-10) and high (11-18) and expressed as per 1-category higher for the estimate. Age and BMI were standardized into per 5y and per 5kg/m2, 
respectively.  
Covariates in the model include age, sex, center, seasonality (sine and cosine function of the day of blood draw), and the other covariates in this table (estimates for dietary vitamin D or 
Mediterranean diet score were not adjusted for food sources of vitamin D [red meat, dairy products, cereal, poultry, processed meat, offal, margarine, butter and mushroom], and vice versa; 
estimates for demographic, lifestyle, dietary factors or lipid markers (HDL-cholesterol, LDL-cholesterol, PUFA, SFA) were not adjusted for plasma hepatic [GGT, ALT or AST] or renal 
markers [creatinine, uric acid]). HDL, high-density lipoprotein; LDL, low-density lipoprotein; SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; ALT, alanine transaminase; AST, 
aspartate transaminase; GGT, gamma-glutamyl transferase.  
†Sample sizes presented are that for the dataset in multiple imputation.  
‡NA, not available; for latitudes (limited study center in some countries) and 25(OH)D2 (limited sample size), the effect estimates were obtained combining all the countries and no meta-
analysis was performed. 
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Supplemental Table 5 Association of total plasma 25(OH)D, as a sum of D2, epimeric and non-epimeric D3, with incident type 2 diabetes: EPIC-InterAct Study 
 
Hazard ratio (95% Confidence Intervals)* 
 Q1 Q2 Q3 Q4 Q5 Per 1-SD 
Total 25(OH)D [sum of non-epimeric 25(OH)D3, 3-epi-25(OH)D3 and 25(OH)D2], nmol/L 
Median (range)† 20.2 (5.68-<26.3) 31.2 (26.3-35.8) 40.1 (35.8-<44.7) 49.7 (44.7-<56.1) 65.4 (56.1-<132.1)   
N cases/ subcohort 2194/2465 1893/2473 1631/2493 1413/2472 1200/2442  
Model 1 1 (ref) 0.82 (0.71, 0.95) 0.64 (0.58, 0.71) 0.53 (0.46, 0.60) 0.43 (0.39, 0.48) 0.71 (0.69, 0.74) 
Model 2 1 (ref) 0.81 (0.72, 0.91) 0.68 (0.60, 0.77) 0.59 (0.52, 0.67) 0.53 (0.47, 0.60) 0.77 (0.74, 0.81) 
Model 3 1 (ref) 0.90 (0.76, 1.06) 0.79 (0.67, 0.94) 0.74 (0.60, 0.92) 0.73 (0.61, 0.88) 0.87 (0.82, 0.92) 
* Hazard ratios (HRs) of type 2 diabetes comparing quintiles (Q2-Q5) of 25(OH)D metabolites with quintile 1 (Q1) or per 1-SD increase of 25(OH)D metabolites, estimated 
from country-specific Prentice-weighted Cox regression models; estimates were combined across countries using random-effects meta-analysis. The present analyses were 
based on complete case analyses excluding participants with missing covariates based on model 4.  
Model 1: Adjusted for age (as underlying timescale), sex (men, women), center, and seasonality (continuous: sine and cosine function of the day of blood draw); 
Model 2: Model 1 + smoking status (current, former, never), physical activity (inactive, moderately inactive, moderately active, active), education (none, primary, technical 
or professional, secondary, higher education), alcohol drinking (never, >0-<6 g/day, 6-<12 g/day, 12-<24 g/day, ≥24 g/day), total energy intake (continuous), Mediterranean 
diet score (low, moderate, high) and plasma lipid biomarkers (continuous: HDL-cholesterol, LDL-cholesterol); 
Model 3: Model 2 + BMI (continuous); 
†Median and range of the 25(OH)D metabolites in each quintile in the InterAct subcohort. 
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Supplemental Table 6 Association of the ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3 with incident type 2 diabetes: EPIC-InterAct Study  
  
 Hazard ratio (95% Confidence Intervals)* 
Model n 3-epi-25(OH)D3 
below LLQ † 
Q1 Q2 Q3 Q4 Q5 Per 1-SD 
Median (range)     0.02 (0.01-<0.03) 0.03 (0.03-<0.04) 0.04 (0.04-<0.05) 0.05 (0.05-<0.06) 0.07 (0.06-0.19)   
N cases/ subcohort   5143/ 7312 485/ 978 576/ 983 640/ 958 712/ 964 775/ 958   
Model 1 8029 1.42 (1.25, 1.60) 1 (ref) 1.16 (0.90, 1.48) 1.23 (1.05, 1.44) 1.35 (1.14, 1.60) 1.41 (1.20, 1.65) 1.15 (1.10, 1.21) 
Model 2 8029 1.27 (1.11, 1.46) 1 (ref) 1.11 (0.90, 1.38) 1.16 (0.97, 1.38) 1.23 (1.02, 1.48) 1.37 (1.15, 1.63) 1.17 (1.11, 1.23) 
Model 3 8029 1.13 (0.98, 1.32) 1 (ref) 1.09 (0.84, 1.41) 1.09 (0.90, 1.33) 1.19 (0.95, 1.47) 1.26 (1.04, 1.52) 1.14 (1.08, 1.21) 
Model 4 8029 1.14 (0.98, 1.32) 1 (ref) 1.09 (0.84, 1.41) 1.10 (0.90, 1.33) 1.19 (0.96, 1.48) 1.26 (1.04, 1.53) 1.14 (1.08, 1.22) 
Model 4, + dietary variables and supplements ‡ 7357 1.12 (0.96, 1.31) 1 (ref) 1.07 (0.82, 1.40) 1.14 (0.91, 1.42) 1.27 (0.96, 1.67) 1.23 (1.00, 1.51) 1.13 (1.06, 1.20) 
Model 4, excluding HbA1C≥6.5%  7431 1.11 (0.95, 1.30) 1 (ref) 1.05 (0.79, 1.39) 1.06 (0.85, 1.32) 1.13 (0.93, 1.38) 1.25 (1.02, 1.52) 1.14 (1.07, 1.21) 
Model 4, excluding first 2 years’ incident T2D 7764 1.14 (0.98, 1.33) 1 (ref) 1.09 (0.84, 1.42) 1.10 (0.91, 1.35) 1.20 (0.97, 1.48) 1.28 (1.05, 1.55) 1.15 (1.07, 1.22) 
Model 4, + baseline HbA1c 7929 1.05 (0.89, 1.24) 1 (ref) 1.02 (0.77, 1.36) 1.14 (0.86, 1.50) 1.15 (0.94, 1.40) 1.18 (0.96, 1.45) 1.14 (1.07, 1.22) 
Model 4, + hepatic and renal function markers § 7859 1.08 (0.92, 1.27) 1 (ref) 1.14 (0.85, 1.51) 1.07 (0.87, 1.30) 1.14 (0.93, 1.39) 1.11 (0.91, 1.37) 1.10 (1.02, 1.18) 
Model 4, + plasma phospholipid SFA, PUFA 8005 1.09 (0.94, 1.27) 1 (ref) 1.05 (0.81, 1.36) 1.04 (0.86, 1.26) 1.13 (0.94, 1.37) 1.19 (0.99, 1.45) 1.12 (1.05, 1.19) 
Model 4+ family history and disease prevalence ǁ  3125 1.14 (0.91, 1.42) 1 (ref) 1.04 (0.77, 1.39) 1.18 (0.88, 1.59) 1.44 (0.97, 2.13) 1.07 (0.79, 1.46) 1.10 (0.96, 1.26) 
Model 4, only including women 4309 1.12 (0.92, 1.37) 1 (ref) 1.06 (0.82, 1.39) 1.03 (0.79, 1.35) 1.39 (1.02, 1.89) 1.18 (0.89, 1.56) 1.12 (1.03, 1.23) 
Model 4, hormone use and menopausal status in women 4126 1.13 (0.92, 1.39) 1 (ref) 1.05 (0.80, 1.39) 1.07 (0.82, 1.41) 1.42 (1.02, 1.97) 1.22 (0.91, 1.63) 1.15 (1.05, 1.26) 
*Hazard ratios (HRs) of type 2 diabetes comparing quintiles (Q2-Q5) of 25(OH)D metabolites with quintile 1 (Q1) or per 1-SD increase of the ratio of 3-epi-25(OH)D3 to 
non-epimeric 25(OH)D3, estimated from country-specific Prentice-weighted Cox regression models; estimates were combined across countries using random-effects meta-
analysis. Model 1-3 is the same as model 1-3 in the main analysis (Table 2), and the model 4 was model 3 + 25(OH)D2 (categorical: below and above the LLQ). N cases/ 
subcohort in each category refers the sample size of model 1 to model 4. 
†This category represents that the ratio is missing because 3-epi-25(OH)D3 is the below LLQ (1 nmol/L); 
‡Dietary variables and supplements include fish, egg, red meat, dairy products, cereal, poultry, processed meat, offal, margarine, butter, mushrooms and vitamin supplement 
use; 
§Hepatic and renal function markers represent alanine transaminase, aspartate transaminase, and gamma-glutamyl transferase, and creatinine, uric acid, respectively. 




Supplemental Table 7 Sensitivity analysis for the association of plasma 25(OH)D metabolites with incident type 2 diabetes: EPIC-InterAct Study 
 
Models  Hazard ratio (95% Confidence Intervals)* 
n Below LLQ Q1 Q2 Q3 Q4 Q5 Per 1-SD 
Non-epimeric 25(OH)D3, nmol/L         
Model 4 20168  1 (ref) 0.88 (0.75, 1.04) 0.73 (0.61, 0.87) 0.74 (0.62, 0.88) 0.62 (0.54, 0.72) 0.81 (0.77, 0.86) 
Model 4, + dietary variables and supplements† 18537  1 (ref) 0.87 (0.73, 1.03) 0.70 (0.57, 0.85) 0.72 (0.59, 0.88) 0.60 (0.51, 0.71) 0.81 (0.77, 0.86) 
Model 4, excluding HbA1C≥6.5%  18555  1 (ref) 0.86 (0.72, 1.04) 0.75 (0.63, 0.88) 0.75 (0.62, 0.89) 0.62 (0.53, 0.72) 0.82 (0.78, 0.87) 
Model 4, excluding first 2 years’ incident T2D 19437  1 (ref) 0.88 (0.75, 1.03) 0.75 (0.63, 0.89) 0.75 (0.63, 0.88) 0.65 (0.56, 0.76) 0.82 (0.78, 0.87) 
Model 4, + baseline HbA1c 19914  1 (ref) 0.88 (0.67, 1.16) 0.76 (0.61, 0.96) 0.75 (0.61, 0.93) 0.68 (0.56, 0.83) 0.84 (0.78, 0.90) 
Model 4, + hepatic and renal function markers‡ 19739  1 (ref) 0.94 (0.77, 1.13) 0.77 (0.61, 0.98) 0.83 (0.66, 1.04) 0.75 (0.62, 0.90) 0.87 (0.82, 0.93) 
Model 4, + plasma phospholipid SFA, PUFA 20100  1 (ref) 0.87 (0.75, 1.01) 0.74 (0.62, 0.89) 0.75 (0.63, 0.89) 0.64 (0.55, 0.75) 0.83 (0.78, 0.87) 
Model 4+ family history and disease prevalence§ 7748  1 (ref) 0.77 (0.60, 0.99) 0.56 (0.43, 0.72) 0.61 (0.50, 0.76) 0.54 (0.42, 0.69) 0.78 (0.72, 0.85) 
Model 4, only including women 11761  1 (ref) 0.82 (0.64, 1.04) 0.65 (0.46, 0.91) 0.77 (0.54, 1.10) 0.59 (0.48, 0.72) 0.83 (0.77, 0.89) 
Model 4, hormone use and menopausal status in women 11334  1 (ref) 0.78 (0.60, 1.01) 0.63 (0.45, 0.88) 0.73 (0.50, 1.07) 0.56 (0.44, 0.71) 0.82 (0.76, 0.88) 
         
3-epi-25(OH)D3, nmol/L         
Model 4 8029 0.92 (0.79, 1.08) 1 (ref) 1.09 (0.85, 1.38) 0.99 (0.82, 1.19) 1.10 (0.92, 1.31) 1.36 (1.08, 1.71) 1.16 (1.09, 1.25) 
Model 4, + dietary variables and supplements† 7357 0.88 (0.76, 1.02) 1 (ref) 1.02 (0.77, 1.36) 0.99 (0.79, 1.22) 1.09 (0.87, 1.37) 1.23 (1.00, 1.50) 1.15 (1.06, 1.24) 
Model 4, excluding HbA1C≥6.5%  7431 0.93 (0.81, 1.08) 1 (ref) 1.08 (0.83, 1.42) 0.99 (0.81, 1.19) 1.06 (0.88, 1.28) 1.36 (1.08, 1.71) 1.16 (1.08, 1.24) 
Model 4, excluding first 2 years’ incident T2D 7764 0.93 (0.80, 1.08) 1 (ref) 1.08 (0.85, 1.38) 1.00 (0.83, 1.20) 1.13 (0.91, 1.40) 1.36 (1.09, 1.70) 1.16 (1.09, 1.25) 
Model 4, + baseline HbA1c 7929 0.87 (0.75, 1.01) 1 (ref) 1.04 (0.75, 1.44) 0.93 (0.76, 1.13) 1.04 (0.86, 1.27) 1.46 (1.11, 1.92) 1.18 (1.10, 1.27) 
Model 4, + hepatic and renal function markers‡ 7859 0.94 (0.81, 1.10) 1 (ref) 1.14 (0.90, 1.45) 1.00 (0.82, 1.22) 1.04 (0.86, 1.27) 1.31 (1.02, 1.67) 1.12 (1.02, 1.22) 
Model 4, + plasma phospholipid SFA, PUFA 8005 0.90 (0.76, 1.07) 1 (ref) 1.04 (0.81, 1.35) 0.97 (0.80, 1.17) 1.07 (0.88, 1.30) 1.26 (1.02, 1.56) 1.13 (1.05, 1.21) 
Model 4+ family history and disease prevalence§  3125 0.80 (0.57, 1.11) 1 (ref) 0.95 (0.61, 1.47) 0.89 (0.55, 1.45) 1.08 (0.80, 1.46) 1.23 (0.82, 1.84) 1.12 (0.99, 1.26) 
Model 4, only including women 4309 0.92 (0.72, 1.17) 1 (ref) 1.09 (0.75, 1.60) 0.96 (0.74, 1.25) 1.27 (0.98, 1.65) 1.51 (1.14, 2.00) 1.09 (0.98, 1.21) 
Model 4, hormone use and menopausal status in women 4126 0.90 (0.69, 1.19) 1 (ref) 1.18 (0.73, 1.92) 0.93 (0.71, 1.22) 1.30 (1.00, 1.70) 1.53 (1.14, 2.05) 1.13 (0.99, 1.30) 
         
25(OH)D2, nmol/L         
Model 4 899 1.29 (0.86, 1.95) 1 (ref) 0.93 (0.52, 1.66) 1.15 (0.68, 1.96) 1.10 (0.62, 1.96) 1.00 (0.58, 1.73) 0.94 (0.76, 1.18) 
Model 4, + dietary variables and supplements† 862 1.27 (0.83, 1.92) 1 (ref) 0.91 (0.50, 1.65) 1.09 (0.63, 1.88) 1.12 (0.63, 2.01) 1.05 (0.60, 1.83) 0.93 (0.72, 1.19) 
Model 4, excluding HbA1C≥6.5%  843 1.32 (0.86, 2.02) 1 (ref) 0.96 (0.53, 1.72) 1.20 (0.69, 2.08) 1.11 (0.61, 2.00) 1.01 (0.57, 1.79) 0.98 (0.77, 1.23) 
Model 4, excluding first 2 years’ incident T2D 866 1.26 (0.83, 1.90) 1 (ref) 0.92 (0.51, 1.65) 1.05 (0.61, 1.81) 1.09 (0.61, 1.95) 0.94 (0.54, 1.65) 0.93 (0.74, 1.17) 
Model 4, + baseline HbA1c 893 1.13 (0.75, 1.69) 1 (ref) 0.84 (0.47, 1.51) 1.07 (0.62, 1.82) 0.97 (0.55, 1.71) 0.93 (0.53, 1.62) 1.04 (0.83, 1.31) 
18 
Supplementary Data 
Model 4, + hepatic and renal function markers‡ 883 1.27 (0.83, 1.94) 1 (ref) 0.93 (0.52, 1.67) 1.20 (0.69, 2.08) 1.09 (0.60, 2.00) 1.13 (0.65, 1.99) 0.96 (0.76, 1.22) 
Model 4, + plasma phospholipid SFA, PUFA 896 1.22 (0.80, 1.84) 1 (ref) 0.93 (0.53, 1.64) 1.08 (0.63, 1.86) 1.02 (0.56, 1.84) 0.99 (0.57, 1.71) 0.95 (0.78, 1.17) 
Model 4+ family history and disease prevalence§  576 1.84 (1.03, 3.28) 1 (ref) 0.95 (0.44, 2.07) 1.50 (0.71, 3.17) 1.36 (0.62, 2.97) 1.53 (0.73, 3.24) 1.21 (0.99, 1.48) 
Model 4, only including women 549 1.52 (0.91, 2.55) 1 (ref) 1.43 (0.61, 3.35) 1.10 (0.53, 2.27) 1.22 (0.51, 2.91) 1.20 (0.60, 2.38) 0.99 (0.76, 1.28) 
Model 4, hormone use and menopausal status in women 529 1.75 (1.02, 3.03) 1 (ref) 1.71 (0.73, 4.02) 1.27 (0.60, 2.69) 1.48 (0.62, 3.57) 1.58 (0.79, 3.16) 1.09 (0.82, 1.44) 
* Hazard ratios (HRs) of type 2 diabetes comparing quintiles (Q2-Q5) of 25(OH)D metabolites with quintile 1 (Q1) or per 1-SD increase of 25(OH)D metabolites, estimated 
from country-specific Prentice-weighted Cox regression models; estimates were combined across countries using random-effects meta-analysis. Effect estimates for 
25(OH)D2 were derived from analysis of the overall EPIC-InterAct data (i.e. not country-specific), due to limited sample size. 1-SD (calculated from the subcohort) was 17.3 
nmol/L for non-epimeric 25(OH)D3, 1.31 nmol/L for 3-epi-25(OH)D3, and 6.52 nmol/L for 25(OH)D2. Model 4 is the same as model 4 in the main analysis (Table 2), 
adjusted for age (as underlying timescale), sex, center, seasonality (sine and cosine function of the day of blood draw), smoking status, physical activity, education, alcohol 
drinking, total energy intake, Mediterranean diet score, circulating lipid biomarkers (HDL-C, LDL-C), BMI and the other two 25(OH)D metabolites. 
†Dietary variables and supplements include fish, egg, red meat, dairy products, cereal, poultry, processed meat, offal, margarine, butter, mushrooms and vitamin supplement 
use. 
‡Hepatic and renal function markers represent alanine transaminase, aspartate transaminase, and gamma-glutamyl transferase, and creatinine, uric acid, respectively. 





Supplemental Table 8 Association of plasma 25(OH)D metabolites (per 1 SD increase) with incident type 
2 diabetes using complete case analysis and multiple imputation: EPIC-InterAct Study 
  
 Complete case analysis  
 
Multiple imputation 
 Model HR (95%CI) I2, % HR (95%CI)* I2, % 
Non-epimeric 25(OH)D3, nmol/L  Cases/ subcohort 8331/ 12345   9671/ 13562  
 Model 1 0.71 (0.69, 0.74) 0  0.70 (0.68, 0.73) 0 
 Model 2 0.77 (0.74, 0.80) 0  0.77 (0.74, 0.80) 0 
 
Model 3 0.86 (0.82, 0.91) 15.7  0.85 (0.81, 0.90) 36.7 
 Model 4 0.81 (0.77, 0.86) 0  0.80 (0.76, 0.84) 0 
3-epi-25(OH)D3, nmol/L Cases/ subcohort 3188/ 5033   3694/5513  
 
Model 1 0.99 (0.94, 1.04) 0  0.99 (0.95, 1.04) 0 
 
Model 2 1.03 (0.97, 1.09) 0  1.03 (0.97, 1.10) 8 
 
Model 3 1.09 (1.02, 1.17) 18.1  1.08 (1.00, 1.17) 30.9 
 Model 4 1.16 (1.09, 1.25) 0  1.17 (1.08, 1.26) 19.5 
25(OH)D2, nmol/L Cases/ subcohort 343/ 572   397/634  
 Model 1 1.00 (0.85, 1.18) NA‡  0.94 (0.79, 1.12) NA‡ 
 Model 2 1.02 (0.84, 1.23) NA  0.95 (0.78, 1.15) NA 
 Model 3 1.03 (0.84, 1.25) NA  0.97 (0.79, 1.18) NA 
 Model 4 0.94 (0.76, 1.18) NA  0.89 (0.72, 1.11) NA 
* Hazard Ratios (HRs) are per 1-standard deviation (study-specific) higher vitamin D metabolite [except for 
25(OH)D2], estimated using country-specific Prentice-weighted Cox regression with multiple imputation (10 
imputed datasets); estimates were then combined across countries using inverse variance-weighted random-
effects meta-analysis. Effect estimates for 25(OH)D2 were derived from analysis of the overall EPIC-InterAct 
data (i.e. not country-specific), due to limited sample size. The sample size of cases/subcohort was 9671/13562 
for epimeric 25(OH)D3, 3694/5513 for 3-epi-25(OH)D3, and 397/634 for 25(OH)D2. 
Model 1: Adjusted for age (as underlying timescale), sex, center, and seasonality (sine and cosine function of 
the day of blood draw); 
Model 2: Model 1+smoking status, physical activity, education, alcohol drinking, total energy intake and 
Mediterranean diet score, and plasma lipid biomarkers (HDL-cholesterol, LDL-cholesterol); 
Model 3: Model 2+BMI. 
Model 4: Model 3 + mutual adjustment for the other two 25(OH)D metabolites [epimeric 25(OH)D3 
(continuous), 3-epi-25(OH)D3 (categorical: below LLQ, Q1, Q2, Q3, Q4, and Q5), or 25(OH)D2 (categorical: 
below and above LLQ)]. Results of the four models from the complete case analysis (already shown in the table 
2) were also presented in the table as a comparison to the results from multiple imputation. 
‡ NA, not available. Effect estimates for 25(OH)D2 were derived from analysis of the overall EPIC-InterAct 




Supplemental Figure 1 Metabolic pathway of vitamin D metabolites. C-3-epimerisation means configuration 
of the hydroxyl bond at the C-3 position between vitamin D metabolites, as indicated in the molecular figure for 
the structure change (direction change of -OH group) from non-epimeric 25(OH)D3 to 3-epi-25(OH)D3 in the 











Supplemental Figure 3 Distribution of baseline plasma 25(OH)D metabolites, dietary vitamin D and vitamin supplement intake by future diabetes case status and 














Supplemental Figure 5 Prospective associations of plasma 25(OH)D metabolites with incident type 2 
diabetes by country: EPIC-InterAct Study 
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Supplemental Figure 6 Association of the ratio of 3-epi-25(OH)D3 to non-epimeric 25(OH)D3 with 




Supplemental Figure S7 Prospective association between plasma 25(OH)D3 metabolites and type 2 
diabetes stratified by BMI categories: EPIC-InterAct Study  
 
